Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Dartmouth-Hitchcock Medical Center (DHMC)
mi
from
Lebanon, NH
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Dartmouth-Hitchcock Medical Center (DHMC)
mi
from
Lebanon, NH
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Low Country Rheumatology
mi
from
Charleston, SC
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Low Country Rheumatology
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Pioneer Research Solutions, Inc.
mi
from
Houston, TX
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Pioneer Research Solutions, Inc.
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
University of Utah Hospital and Clinics
mi
from
Salt Lake City, UT
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
University of Utah Hospital and Clinics
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Dynacare Laboratories (Specimen Processing for Shipment)
mi
from
Seattle, WA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Dynacare Laboratories (Specimen Processing for Shipment)
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Seattle Rheumatology Associates
mi
from
Seattle, WA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Seattle Rheumatology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Swedish Medical Center
mi
from
Seattle, WA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Rheumatology Research Unit
mi
from
Maroochydore,
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Rheumatology Research Unit
mi
from
Maroochydore,
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Advances In Medicine (X-Rays)
mi
from
Rancho Mirage, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Advances In Medicine (X-Rays)
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Drug Shipment/Storage: Huntsman Cancer Hospital at the University of Utah
mi
from
Salt Lake City, UT
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Drug Shipment/Storage: Huntsman Cancer Hospital at the University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Investigational Drug Service Pharmacy, Swedish Medical Center.
mi
from
Seattle, WA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Investigational Drug Service Pharmacy, Swedish Medical Center.
mi
from
Seattle, WA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Rheumatology Associates, PC
mi
from
Birmingham, AL
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Rheumatology Associates, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Medvin Clinical Research
mi
from
Covina, CA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Medvin Clinical Research
mi
from
Covina, CA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
mi
from
Fullerton, CA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
mi
from
Fullerton, CA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Ronald Reagan UCLA Medical Center - Drug Information Center
mi
from
Los Angeles, CA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Ronald Reagan UCLA Medical Center - Drug Information Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
San Diego Arthritis Medical Clinic
mi
from
San Diego, CA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
San Diego Arthritis Medical Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Stanford Hospital and Clinics
mi
from
Stanford, CA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
New England Research Associates, Llc
mi
from
Trumbull, CT
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
New England Research Associates, Llc
mi
from
Trumbull, CT
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Rheumatology Associates of Central Florida
mi
from
Orlando, FL
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Rheumatology Associates of Central Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Millennium Research
mi
from
Ormond Beach, FL
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Millennium Research
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
The Arthritis Center
mi
from
Palm Harbor, FL
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
The Arthritis Center
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Integral Rheumatology & Immunology Specialists (IRIS)
mi
from
Plantation, FL
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Integral Rheumatology & Immunology Specialists (IRIS)
mi
from
Plantation, FL
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
St. Luke's Intermountain Research Center
mi
from
Boise, ID
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
St. Luke's Intermountain Research Center
mi
from
Boise, ID
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Covance Central Laboratory Service
mi
from
Indianapolis, IN
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Covance Central Laboratory Service
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Bluegrass Community Research, Inc
mi
from
Lexington, KY
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Bluegrass Community Research, Inc
mi
from
Lexington, KY
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Clayton Medical Research
mi
from
St. Louis, MO
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Clayton Medical Research
mi
from
St. Louis, MO
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Physician Research Collaboration
mi
from
Lincoln, NE
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Dartmouth-Hitchcock Medical Center (DHMC)
mi
from
Lebanon, NH
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Dartmouth-Hitchcock Medical Center (DHMC)
mi
from
Lebanon, NH
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Cincinnati Rheumatic Disease Study Group
mi
from
Cincinnati, OH
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Cincinnati Rheumatic Disease Study Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
University Hospitals Case Medical Center - Department of Dermatology
mi
from
Cleveland, OH
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
University Hospitals Case Medical Center - Department of Dermatology
mi
from
Cleveland, OH
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
East Penn Rheumatology Associates, P.C.
mi
from
Bethlehem, PA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
East Penn Rheumatology Associates, P.C.
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Low Country Rheumatology
mi
from
Charleston, SC
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Low Country Rheumatology
mi
from
Charleston, SC
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
The Arthritis Clinic
mi
from
Jackson, TN
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
The Arthritis Clinic
mi
from
Jackson, TN
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
West Tennessee Research Institute
mi
from
Jackson, TN
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
West Tennessee Research Institute
mi
from
Jackson, TN
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Metroplex Clinical Research Center
mi
from
Dallas, TX
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Metroplex Clinical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Pioneer Research Solutions, Inc.
mi
from
Houston, TX
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Pioneer Research Solutions, Inc.
mi
from
Houston, TX
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
University of Utah Hospital and Clinics
mi
from
Salt Lake City, UT
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
University of Utah Hospital and Clinics
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Seattle Rheumatology Associates
mi
from
Seattle, WA
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Seattle Rheumatology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Florida Medical Clinic
mi
from
Zephyrhills, FL
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Florida Medical Clinic
mi
from
Zephyrhills, FL
Click here to add this to my saved trials